Newsfeeds - Spark Newswire

2 minute read

Fintech
News

Aptinyx Reports Secured $50M Growth Capital Credit Facility From K2 HealthVentures

Today, 9:39 AM

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV).

APTX

6 minute read

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data

By Shanthi Rexaline

Today, 9:39 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19)

ABVC

3 minute read

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

By Shanthi Rexaline

Today, 9:39 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18)

ABBV

10 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 9:39 AM

Wednesday morning, 136 companies reached new 52-week lows.

ADMA

6 minute read

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline

By Shanthi Rexaline

Today, 9:39 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)

ABBV

8 minute read

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business

By Shanthi Rexaline

Today, 9:39 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)

ABSI

1 minute read

Aptinyx Q2 EPS $(0.29) Misses $(0.25) Estimate

By Benzinga Newsdesk

Today, 9:39 AM

Aptinyx (NASDAQ:APTX) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.25) by 16 percent. This is a 7.41 percent decrease over losses of $(0.27) per share from the same

APTX